Anti-fibrotic effects of chronic treatment with the selective FXR agonist obeticholic acid in the bleomycin-induced rat model of pulmonary fibrosis

Journal of Steroid Biochemistry and Molecular Biology

Volumn 168, Issue , 2017, Pages 26-37

  Comeglio, Paolo ^a   Filippi, Sandra ^b   Sarchielli, Erica ^a   Morelli, Annamaria ^a   Cellai, Ilaria ^a   Corcetto, Francesca ^a   Corno, Chiara ^a   Maneschi, Elena ^a   Pini, Alessandro ^a   Adorini, Luciano ^c   Vannelli, Gabriella Barbara ^a   Maggi, Mario ^a,d   Vignozzi, Linda ^a,d  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c INTERCEPT PHARMACEUTICALS   (United States)

^d NATIONAL INSTITUTE OF BIOSTRUCTURES AND BIOSYSTEMS   (Italy)

Author keywords

Bleomycin; Epithelial to mesenchymal cell transition; Farnesoid X Receptor; Inflammation; Obeticholic acid; Pulmonary fibrosis

Indexed keywords

ANTIFIBROTIC AGENT; COLLAGEN; FARNESOID X RECEPTOR; GELATINASE A; GELATINASE B; INTERLEUKIN 1BETA; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; OBETICHOLIC ACID; PIRFENIDONE; THYROID TRANSCRIPTION FACTOR 1; TRANSFORMING GROWTH FACTOR BETA1; BLEOMYCIN; CELL RECEPTOR; CHENODEOXYCHOLIC ACID; FARNESOID X-ACTIVATED RECEPTOR;

AIRWAY RESISTANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ARTIFICIAL VENTILATION; BLEOMYCIN-INDUCED PULMONARY FIBROSIS; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; HEART RIGHT VENTRICLE; LIVER WEIGHT; LONG TERM CARE; LUNG ALVEOLUS; LUNG FUNCTION; LUNG INFLATION; LUNG INJURY; LUNG INTERSTITIUM; NONHUMAN; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RAT; UPREGULATION; AGONISTS; AIRWAY REMODELING; ANALOGS AND DERIVATIVES; ANIMAL; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; FIBROSIS; GENE EXPRESSION PROFILING; HEART VENTRICLE REMODELING; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LUNG; MALE; METABOLISM; PATHOLOGY; PULMONARY FIBROSIS; SPRAGUE DAWLEY RAT;

AIRWAY REMODELING; ANIMALS; BLEOMYCIN; CHENODEOXYCHOLIC ACID; COLLAGEN; DISEASE MODELS, ANIMAL; FIBROSIS; GENE EXPRESSION PROFILING; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LUNG; MALE; PULMONARY ALVEOLI; PULMONARY FIBROSIS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CYTOPLASMIC AND NUCLEAR; VENTRICULAR REMODELING;

EID: 85011266692     PISSN: 09600760     EISSN: 18791220     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2017.01.010     Document Type: Article

References (44)

1. [1] Sgalla, G., Biffi, A., Richeldi, L., Idiopathic pulmonary fibrosis: diagnosis, epidemiology and natural history. Respirology 21 (2016), 427–437, 10.1111/resp.12683.
2. [2] King, T.E. Jr., Pardo, A., Selman, M., Idiopathic pulmonary fibrosis. Lancet 378 (2011), 1949–1961.
3. [3] Schürch, W., Seemayer, T.A., Gabbiani, G., The myofibroblast: a quarter century after its discovery. Am. J. Surg. Pathol. 22 (1998), 141–147.
4. [4] Serini, G., Gabbiani, G., Mechanisms of myofibroblast activity and phenotypic modulation Exp. Cell. Res. 250 (1999), 273–283.
5. [5] Phan, S.H., The myofibroblast in pulmonary fibrosis. Chest 122 (2002), 286S–289S.
6. [6] Kalluri, R., Neilson, E.G., Epithelial-mesenchymal transition and its implications for fibrosis. J. Clin. Invest. 112 (2003), 1776–1784.
7. [7] Willis, B.C., Liebler, J.M., Luby-Phelps, K., Nicholson, A.G., Crandall, E.D., du Bois, R.M., et al. Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-beta1: potential role in idiopathic pulmonary fibrosis. Am. J. Pathol. 166 (2005), 1321–1332.
8. [8] Kim, K.K., Kugler, M.C., Wolters, P.J., Robillard, L., Galvez, M.G., Brumwell, A.N., et al. Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix. Proc. Natl. Acad. Sci. U. S. A. 103 (2006), 13180–13185.
9. [9] Kasai, H., Allen, J.T., Mason, R.M., Kamimura, T., Zhang, Z., TGF-beta1 induces human alveolar epithelial to mesenchymal cell transition (EMT). Respir. Res., 6, 2005, 56.
10. [10] Fernandez, I.E., Eickelberg, O., The impact of TGF-β on lung fibrosis: from targeting to biomarkers. Proc. Am. Thorac Soc. 9 (2012), 111–116, 10.1513/pats.201203-023AW.
11. [11] Hajra, K.M., Chen, D.Y., Fearon, E.R., The SLUG zinc-finger protein represses E-cadherin in breast cancer. Cancer Res. 62 (2002), 1613–1618.
12. [12] Bolós, V., Peinado, H., Pérez-Moreno, M.A., Fraga, M.F., Esteller, M., Cano, A., The transcription factor Slug represses E-cadherin expression and induces epithelial to mesenchymal transitions: a comparison with Snail and E47 repressors. J. Cell Sci. 116 (2003), 499–511.
13. [13] Raghu, G., Selman, M., Nintedanib and pirfenidone. New antifibrotic treatments indicated for idiopathic pulmonary fibrosis offer hopes and raises questions. Am. J. Respir. Crit. Care Med. 191 (2015), 252–254, 10.1164/rccm.201411-2044ED.
14. [14] Spagnolo, P., Maher, T.M., Richeldi, L., Idiopathic pulmonary fibrosis: recent advances on pharmacological therapy. Pharmacol. Ther. 152 (2015), 18–27, 10.1016/j.pharmthera.2015.04.005.
15. [15] Moeller, A., Ask, K., Warburton, D., Gauldie, J., Kolb, M., The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis?. Int. J. Biochem. Cell Biol. 40 (2008), 362–382.
16. [16] Moore, B.B., Hogaboam, C.M., Murine models of pulmonary fibrosis. Am. J. Physiol. Lung Cell. Mol. Physiol. 294 (2008), L152–L160.
17. [17] Mouratis, M.A., Aidinis, V., Modeling pulmonary fibrosis with bleomycin. Curr. Opin. Pulm. Med. 17 (2011), 355–361, 10.1097/MCP.0b013e328349ac2b.
18. [18] Lefebvre, P., Cariou, B., Lien, F., Kuipers, F., Staels, B., Role of bile acids and bile acid receptors in metabolic regulation. Physiol. Rev. 89 (2009), 147–191, 10.1152/physrev.00010.2008.
19. [19] Ali, A.H., Carey, E.J., Lindor, K.D., Recent advances in the development of farnesoid X receptor agonists. Ann. Transl. Med., 3, 2015, 5, 10.3978/j.issn.2305-5839.2014.12.06.
20. [20] Adorini, L., Pruzanski, M., Shapiro, D., Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis. Drug Discov. Today 17 (2012), 988–997, 10.1016/j.drudis.2012.05.012.
21. [21] Neuschwander-Tetri, B.A., Loomba, R., Sanyal, A.J., Lavine, J.E., Van Natta, M.L., Abdelmalek, M.F., et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 385 (2015), 956–965, 10.1016/S0140-6736(14)61933-4.
22. [22] Angulo, P., Kleiner, D.E., Dam-Larsen, S., Adams, L.A., Bjornsson, E.S., Charatcharoenwitthaya, P., et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 149 (2015), 389–397, 10.1053/j.gastro.2015.04.043.
23. [23] Wang, X.X., Jiang, T., Shen, Y., Adorini, L., Pruzanski, M., Gonzalez, F.J., et al. The farnesoid X receptor modulates renal lipid metabolism and diet-induced renal inflammation, fibrosis, and proteinuria. Am. J. Physiol. Renal Physiol. 297 (2009), F1587–F1596, 10.1152/ajprenal.00404.2009.
24. [24] Wang, X.X., Jiang, T., Shen, Y., Caldas, Y., Miyazaki-Anzai, S., Santamaria, H., et al. Diabetic nephropathy is accelerated by farnesoid X receptor deficiency and inhibited by farnesoid X receptor activation in a type 1 diabetes model. Diabetes 59 (2010), 2916–2927, 10.2337/db10-0019.
25. [25] Zhou, B., Feng, B., Qin, Z., Zhao, Y., Chen, Y., Shi, Z., et al. Activation of farnesoid X receptor downregulates visfatin and attenuates diabetic nephropathy. Mol. Cell. Endocrinol. 419 (2016), 72–82, 10.1016/j.mce.2015.10.001.
26. [26] Vignozzi, L., Morelli, A., Cellai, I., Filippi, S., Comeglio, P., Sarchielli, E., et al. Cardiopulmonary protective effects of the selective FXR agonist obeticholic acid in the rat model of monocrotaline-induced pulmonary hypertension. J. Steroid. Biochem. Mol. Biol. 165 (2017), 277–292, 10.1016/j.jsbmb.2016.07.004.
27. [27] Schaefer, C.J., Ruhrmund, D.W., Pan, L., Seiwert, S.D., Kossen, K., Antifibrotic activities of pirfenidone in animal models. Eur. Respir. Rev. 20 (2011), 85–97.
28. [28] Morelli, A., Filippi, S., Comeglio, P., Sarchielli, E., Chavalmane, A.K., Vignozzi, L., et al. Acute vardenafil administration improves bladder oxygenation in spontaneously hyper-tensive rats. J. Sex. Med. 7 (2010), 107–120.
29. [29] Pini, A., Viappiani, S., Bolla, M., Masini, E., Bani, D., Prevention of bleomycin-induced lung fibrosis in mice by a novel approach of parallel inhibition of cyclooxygenase and nitric-oxide donation using NCX 466, a prototype cyclooxygenase inhibitor and nitric-oxide donor. J. Pharmacol. Exp. Ther. 341 (2012), 493–499, 10.1124/jpet.111.190660.
30. [30] Della Latta, V., Cecchettini, A., Del Ry, S., Morales, M.A., Bleomycin in the setting of lung fibrosis induction: from biological mechanisms to counteractions. Pharmacol. Res. 97 (2015), 122–130, 10.1016/j.phrs.2015.04.012.
31. [31] Yao, H.W., Xie, Q.M., Chen, J.Q., Deng, Y.M., Tang, H.F., TGF-beta1 induces alveolar epithelial to mesenchymal transition in vitro. Life Sci. 76 (2004), 29–37.
32. [32] Xu, G.P., Li, Q.Q., Cao, X.X., Chen, Q., Zhao, Z.H., Diao, Z.Q., et al. The effect of TGF-β1 and Smad7 gene transfer on the phenotypic changes of rat alveolar epithelial cells. Cell. Mol. Biol. Lett. 12 (2007), 457–472, 10.2478/s11658-007-0018-x.
33. [33] Jayachandran, A., Königshoff, M., Yu, H., Rupniewska, E., Hecker, M., Klepetko, W., et al. SNAI transcription factors mediate epithelial-mesenchymal transition in lung fibrosis. Thorax 64 (2009), 1053–1061, 10.1136/thx.2009.121798.
34. [34] Shahar, I., Fireman, E., Topilsky, M., Grief, J., Kivity, S., Spirer, Z., et al. Effect of IL-6 on alveolar fibroblast proliferation in interstitial lung diseases. Clin. Immunol. Immunopathol. 79 (1996), 244–251.
35. [35] Fielding, C.A., Jones, G.W., McLoughlin, R.M., McLeod, L., Hammond, V.J., Uceda, J., et al. Interleukin-6 signaling drives fibrosis in unresolved inflammation. Immunity 40 (2014), 40–50, 10.1016/j.immuni.2013.10.022.
36. [36] Takizawa, H., Satoh, M., Okazaki, H., Matsuzaki, G., Suzuki, N., Ishii, A., et al. Increased IL-6 and IL-8 in bronchoalveolar lavage fluids (BALF) from patients with sarcoidosis: correlation with the clinical parameters. Clin. Exp. Immunol. 107 (1997), 175–181.
37. [37] Aumiller, V., Balsara, N., Wilhelm, J., Günther, A., Königshoff, M., WNT/β-catenin signaling induces IL-1β expression by alveolar epithelial cells in pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 49 (2013), 96–104, 10.1165/rcmb.2012-0524OC.
38. [38] O'Donoghue, R.J., Knight, D.A., Richards, C.D., Prêle, C.M., Lau, H.L., Jarnicki, A.G., et al. Genetic partitioning of interleukin-6 signalling in mice dissociates Stat3 from Smad3-mediated lung fibrosis. EMBO Mol. Med. 4 (2012), 939–951, 10.1002/emmm.201100604.
39. [39] Gasse, P., Mary, C., Guenon, I., Noulin, N., Charron, S., Schnyder-Candrian, S., et al. IL-1R1/MyD88 signaling and the inflammasome are essential in pulmonary inflammation and fibrosis in mice. J. Clin. Invest. 117 (2007), 3786–3799.
40. [40] Wilson, M.S., Madala, S.K., Ramalingam, T.R., Gochuico, B.R., Rosas, I.O., Cheever, A.W., et al. Bleomycin and IL-1beta-mediated pulmonary fibrosis is IL-17A dependent. J. Exp. Med. 207 (2010), 535–552, 10.1084/jem.20092121.
41. [41] Zhang, L., Li, T., Yu, D., Forman, B.M., Huang, W., FXR protects lung from lipopolysaccharide-induced acute injury. Mol. Endocrinol. 26 (2012), 27–36, 10.1210/me.2011-0042.
42. [42] Zhou, C., Shi, Y., Li, J., Zhang, W., Wang, Y., Liu, Y., et al. The effects of taurochenodeoxycholic acid in preventing pulmonary fibrosis in mice. Pak. J. Pharm. Sci. 26 (2013), 761–765.
43. [43] Pardo, A., Cabrera, S., Maldonado, M., Selman, M., Role of matrix metalloproteinases in the pathogenesis of idiopathic pulmonary fibrosis. Respir. Res., 17, 2016, 23, 10.1186/s12931-016-0343-6.
44. [44] Yu, Q., Stamenkovic, I., Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-β and promotes tumor invasion and angiogenesis. Genes Dev. 14 (2000), 163–176.